Mirtazapine Almus (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors. This dual action raises the levels of norepinephrine and serotonin in the brain, producing an antidepressant effect.

The appropriate dose of mirtazapine is individualized and set by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions are made in consultation with a healthcare professional.

To order Mirtazapine Almus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine differs from SSRIs by its NaSSA mechanism, which increases both norepinephrine and serotonin while blocking certain serotonin receptors. This profile often results in stronger sedative and appetite‑stimulating effects, making it useful when insomnia or weight gain are therapeutic goals, whereas SSRIs typically have a more activating profile.

Mirtazapine Almus should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Mirtazapine Almus is taken orally, usually once daily in the evening because of its sedative effect. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the early weeks of therapy. Patients should be monitored closely for signs of infection, rash, or changes in mood.

Mirtazapine should be avoided in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment without appropriate dose adjustment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate manic episodes.